Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial

Anne Laure Sellier-Leclerc; Daniella Magen; Hadas Shasha-Lavsky; Eva Simkova; Arnaud Devresse; Fitsum Guebre-Egziabher; Mini Michael; John C. Lieske; Yaacov Frishberg; Sevcan A. Bakkaloglu; Chebl Mourani; Rola Saqan; Richard Singer; Isabella Guzzo; Nune Makarova; Richard Willey; Cristin Kaspar; John M. Gansner; Jaap W. Groothoff

doi:10.1053/j.ajkd.2025.01.016

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial

Anne Laure Sellier-Leclerc, Daniella Magen, Hadas Shasha-Lavsky, Eva Simkova, Arnaud Devresse, Fitsum Guebre-Egziabher, Mini Michael, John C. Lieske, Yaacov Frishberg, Sevcan A. Bakkaloglu, Chebl Mourani, Rola Saqan, Richard Singer, Isabella Guzzo, Nune Makarova, Richard Willey, Cristin Kaspar, John M. Gansner, Jaap W. Groothoff

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	285-288
Number of pages	4
Journal	American Journal of Kidney Diseases
Volume	86
Issue number	2
Early online date	13 Mar 2025
DOIs	https://doi.org/10.1053/j.ajkd.2025.01.016
State	E-pub ahead of print - 13 Mar 2025
Externally published	Yes

Access to Document

10.1053/j.ajkd.2025.01.016

Cite this

Sellier-Leclerc, A. L., Magen, D., Shasha-Lavsky, H., Simkova, E., Devresse, A., Guebre-Egziabher, F., Michael, M., Lieske, J. C., Frishberg, Y., Bakkaloglu, S. A., Mourani, C., Saqan, R., Singer, R., Guzzo, I., Makarova, N., Willey, R., Kaspar, C., Gansner, J. M., & Groothoff, J. W. (2025). Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial. American Journal of Kidney Diseases, 86(2), 285-288. Advance online publication. https://doi.org/10.1053/j.ajkd.2025.01.016

@article{3fa1e7b1d8b148fd9a85662fc45dfcad,

title = "Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial",

author = "Sellier-Leclerc, \{Anne Laure\} and Daniella Magen and Hadas Shasha-Lavsky and Eva Simkova and Arnaud Devresse and Fitsum Guebre-Egziabher and Mini Michael and Lieske, \{John C.\} and Yaacov Frishberg and Bakkaloglu, \{Sevcan A.\} and Chebl Mourani and Rola Saqan and Richard Singer and Isabella Guzzo and Nune Makarova and Richard Willey and Cristin Kaspar and Gansner, \{John M.\} and Groothoff, \{Jaap W.\}",

year = "2025",

month = mar,

day = "13",

doi = "10.1053/j.ajkd.2025.01.016",

language = "אנגלית",

volume = "86",

pages = "285--288",

journal = "American Journal of Kidney Diseases",

issn = "0272-6386",

publisher = "W.B. Saunders",

number = "2",

}

Sellier-Leclerc, AL, Magen, D, Shasha-Lavsky, H, Simkova, E, Devresse, A, Guebre-Egziabher, F, Michael, M, Lieske, JC, Frishberg, Y, Bakkaloglu, SA, Mourani, C, Saqan, R, Singer, R, Guzzo, I, Makarova, N, Willey, R, Kaspar, C, Gansner, JM & Groothoff, JW 2025, 'Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial', American Journal of Kidney Diseases, vol. 86, no. 2, pp. 285-288. https://doi.org/10.1053/j.ajkd.2025.01.016

TY - JOUR

T1 - Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1

T2 - 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial

AU - Sellier-Leclerc, Anne Laure

AU - Magen, Daniella

AU - Shasha-Lavsky, Hadas

AU - Simkova, Eva

AU - Devresse, Arnaud

AU - Guebre-Egziabher, Fitsum

AU - Michael, Mini

AU - Lieske, John C.

AU - Frishberg, Yaacov

AU - Bakkaloglu, Sevcan A.

AU - Mourani, Chebl

AU - Saqan, Rola

AU - Singer, Richard

AU - Guzzo, Isabella

AU - Makarova, Nune

AU - Willey, Richard

AU - Kaspar, Cristin

AU - Gansner, John M.

AU - Groothoff, Jaap W.

PY - 2025/3/13

Y1 - 2025/3/13

UR - http://www.scopus.com/inward/record.url?scp=105006933471&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2025.01.016

DO - 10.1053/j.ajkd.2025.01.016

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 40086686

AN - SCOPUS:105006933471

SN - 0272-6386

VL - 86

SP - 285

EP - 288

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

IS - 2

ER -

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial

Access to Document

Other files and links

Cite this